Blog footer

Digital Pharma: Pfizer and Boehringer’s online COPD awareness

pharmafile | November 12, 2010 | News story | Medical Communications Boehringer Ingelheim, COPD, Digital Pharma blog, Managing COPD, NICE, Pfizer, Spiriva, chronic obstructive pulmonary disease 

Pfizer and Boehringer Ingelheim have launched an online campaign to publicise the latest NICE guidelines on COPD to healthcare professionals in the UK.

The pharma companies’ Managing COPD website also includes an overview of the evidence for Spiriva, the blockbuster drug they co-market, and a patient case study offering healthcare professionals continuing professional development (CPD) points.

The new website adds to COPD Exchange, a peer-reviewed medical education site about chronic obstructive pulmonary disease (COPD) Pfizer and Boehringer launched last year.

Managing COPD was developed in association with Pulse and promoted through the Royal College of Nursing.

It has a separate section for patients, which includes information on COPD, the types of medicines available and a download link for Spiriva’s patient information leaftlet.

NICE issued updated COPD guidelines in June this year, which include reclassified definitions of the stages of COPD and new recommendations on the selection of treatments.

Earlier this year GlaxoSmithKline, whose Seretide is the market-leading COPD treatment, launched its ‘Paper To Patient’ initiative, which aims to “bring best practice to life in COPD”.

It’s already held a series of meetings on the National COPD Strategy and NICE guidelines, and plans to launch online interactive training and ‘virtual patients’ in the near future.

Meanwhile, Pfizer and Boehringer are running a local pilot for a public-facing disease awareness campaign in the UK.

Their COPD: Know It, Check It, Treat It campaign was recently unveiled in Salford, Greater Manchester, and involves a range of on- and offline activities.

COPD, a catch-all term for a range of conditions including chronic bronchitis and emphysema, is thought to affect around 3.7 million people in the UK, over three quarters of whom are unaware that they have the disease.

Dominic Tyer is web editor for Pharmafocus and InPharm.com and the author of the Digital Pharma blog He can be contacted via email, Twitter or LinkedIn.

Related Content

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Emblaveo (aztreonam-avibactam) …

NICE recommends migraine treatment for NHS use

The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s …

Boehringer Ingelheim’s Spevigo gains additional approvals in US and China

Boehringer Ingelheim has announced that Spevigo (spesolimab-sbzo) has been approved by the US Food and …

Latest content